drugset / Trial / NCT05990985
The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.
Not yet recruiting
20 enrolled
The First Hospital of Jilin University
CSPC Ouyi Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
A clinical study was conducted to evaluate the efficacy and safety of the RCMOP regimen sequential therapy as a first-line treatment for patients with intermediate-to-high risk diffuse large B-cell lymphoma who had incomplete remission.
Timeline
- Start
- 2023-09-01
- Primary completion
- 2024-08-01
- Completion
- 2026-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Subject | Mitoxantrone | Small molecule | 18 mg/m2 | Intravenous |
| Subject | Prednisolone | Other / unclassified | 100 mg | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |